Olshansky Brian, Sami Magdi, Rubin Andrew, Kostis John, Shorofsky Stephen, Slee April, Greene H Leon
University of Iowa, Iowa City, Iowa, USA.
Am J Cardiol. 2005 Feb 1;95(3):404-5. doi: 10.1016/j.amjcard.2004.09.044.
In the Atrial Fibrillation Follow-up Investigation of Rhythm Management study, preexisting pulmonary disease did not preclude the use of amiodarone. Preexisting pulmonary disease was associated with a higher risk of pulmonary death and had a higher risk of diagnosed amiodarone pulmonary toxicity. However, use of amiodarone in the presence of preexisting pulmonary disease did not increase pulmonary death and all-cause mortality rates. Cautious use of amiodarone to treat atrial fibrillation appears acceptable in elderly patients with atrial fibrillation, even if preexisting pulmonary disease is present.
在房颤节律管理随访研究中，既往存在的肺部疾病并不妨碍使用胺碘酮。既往存在的肺部疾病与肺部死亡风险较高相关，且被诊断为胺碘酮肺毒性的风险也较高。然而，在已有肺部疾病的情况下使用胺碘酮并不会增加肺部死亡和全因死亡率。对于老年房颤患者，即使存在既往肺部疾病，谨慎使用胺碘酮治疗房颤似乎是可以接受的。
